The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial

ObjectiveTo investigate the effects of Ginko biloba extract (EGb) administration on T lymphocyte subsets and superoxide dismutase (SOD) levels in schizophrenia.MethodsOne hundred and nine schizophrenic inpatients were randomly assigned to 12 weeks of treatment with 360 mg/day of EGb plus a stable dose of 0.25 mg kg−1 day−1 of haloperidol and placebo plus the same dose of haloperidol using a double-blind design. Clinical efficacy was determined using the Brief Psychiatric Rating Scale (BPRS), Scale for Assessment of Positive Symptoms, and Scale for Assessment of Negative Symptoms. T lymphocytes (CD3+), T helper cells (CD4+), T suppressor cells (CD8+), and IL-2-secreting cells were measured using the alkaline phosphatase/antialkaline phosphatase technique; and SOD levels were measured by radioimmunometric assay at baseline and at posttreatment, as compared to 30 sex- and age-matched normal subjects.ResultsPatients demonstrated significantly lower CD3+, CD4+, and IL-2-secreting cells, together with CD4/CD8 ratio, and significantly higher blood SOD levels than did healthy controls at baseline. There was a significantly negative relationship between SOD and CD4+ cells in the schizophrenic group at baseline. After a 12-week treatment, CD3+, CD4+, and IL-2-secreting cells, together with CD4/CD8 ratio, showed a significant increase, but a significant decrease in SOD levels in the EGb group. There was only a significant increase in CD4+ cells but no change in SOD levels in the placebo group. There was a significant correlation between the change in CD4+ cells at posttreatment vs pretreatment and a reduction of BPRS total score in the whole patient group.ConclusionsEGb may improve the decreased peripheral immune functions in schizophrenia. The beneficial effects of EGb on the immune systems and the improvement of schizophrenic symptoms may be medicated through its antioxidant activity.

[1]  M. Ackenheil,et al.  T‐cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy , 1993, Acta psychiatrica Scandinavica.

[2]  Jeffrey K. Yao,et al.  An Overview of the Evidence and Its Therapeutic Implications , 2001 .

[3]  Guiyou Zhang,et al.  Effects of Ginkgo biloba extract (EGb 761) on hydroxyl radical-induced thymocyte apoptosis and on age-related thymic atrophy and peripheral immune dysfunctions in mice , 2003, Mechanisms of Ageing and Development.

[4]  X. Zhang,et al.  Decreased production of interleukin-2 (IL-2), IL-2 secreting cells and CD4+ cells in medication-free patients with schizophrenia. , 2002, Journal of psychiatric research.

[5]  C. Caruso,et al.  Biological significance of soluble IL-2 receptor , 1993, Mediators of inflammation.

[6]  G. Kemmler,et al.  T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients , 1999, Schizophrenia Research.

[7]  P. Marrack,et al.  Reactive oxygen species regulate activation-induced T cell apoptosis. , 1999, Immunity.

[8]  J. Lohr,et al.  Oxidative Mechanisms and Tardive Dyskinesia , 2003, CNS drugs.

[9]  M. Schwarz,et al.  The role of immune function in schizophrenia: an overview , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[10]  G. Spindler,et al.  An Integrative View , 1992 .

[11]  W. Browner,et al.  Ginkgo biloba: a living fossil. , 2000, The American journal of medicine.

[12]  A. M. Puebla-Pérez,et al.  Effect of Ginkgo biloba extract, EGb 761, on the cellular immune response in a hypothalamic-pituitary-adrenal axis activation model in the rat. , 2003, International immunopharmacology.

[13]  A. Fietta,et al.  Assessment of lymphocyte subsets and neutrophil leukocyte function in chronic psychiatric patients on long-term drug therapy , 1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[14]  X. Zhang,et al.  A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. , 2001, The Journal of clinical psychiatry.

[15]  X. Zhang,et al.  The Effect of Extract of Ginkgo Biloba Added to Haloperidol on Superoxide Dismutase in Inpatients With Chronic Schizophrenia , 2001, Journal of clinical psychopharmacology.

[16]  M. Schwarz,et al.  The Immune System and Schizophrenia: An Integrative View , 2000, Annals of the New York Academy of Sciences.

[17]  H. Lôo,et al.  Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. , 1989, The American journal of psychiatry.

[18]  Paul F. Smith,et al.  The CNS effects of Ginkgo biloba extracts and ginkgolide B , 2002, Progress in Neurobiology.